Enveda Biosciences Raises $311 Million for AI Drug Platform

Enveda Biosciences, a clinical-stage biotechnology company, has closed a $311 million Series E funding round ^[1]. The financing will scale its AI-native platform, PRISM, which identifies drug candidates from natural chemical libraries ^[1][2]. The platform specifically targets inflammatory and metabolic conditions ^[1].

The funding follows successful early clinical results for AI-discovered treatments for atopic dermatitis and obesity ^[1][3]. Enveda aims to modernize pharmaceutical development by mining natural compounds ^[1]. This round marks the company's third megaround, reflecting high investor interest in AI-driven medicine ^[3].